NWPHF OTC
Newron Pharmaceuticals S.p.A.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
$20.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$416.1M
52W Range9.36-20
Volume986
Avg Volume676
Beta0.74
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOStefan Weber
Employees22
SectorHealthcare
IndustryBiotechnology
IPO Date2017-08-30
Websitenewron.com
Via Antonio Meucci 3
Bresso, MI 20091
IT
Bresso, MI 20091
IT
39 02 610 3461
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing treatments for disorders affecting the central and peripheral nervous systems, as well as pain conditions. Operating in both Italy and the United States, the company's portfolio includes Xadago (safinamide), an approved therapy for Parkinson's disease, which is also under investigation for levodopa-induced dyskinesia. Additionally, Newron is developing Evenamide for schizophrenia and its treatment-resistant form, and Ralfinamide for specific orphan indications in neuropathic pain. Established in 1999, Newron Pharmaceuticals S.p.A. maintains its headquarters in Bresso, Italy.
Latest News
No recent news
Recent Insider Trades
No insider trades found